United Therapeutics (UTHR) Return on Capital Employed (2010 - 2026)
United Therapeutics (UTHR) posted Return on Capital Employed of 21.43% for Q1 2026, up 1.31% sequentially from 21.16% in Q4 2025, and up 89.0% YoY from 11.34% in Q1 2025.
United Therapeutics (UTHR) Return on Capital Employed (2010 - 2026) Analysis & Trends
United Therapeutics has reported Return on Capital Employed for 17 years, with the latest figure at 21.43% in Q1 2026.
- Quarterly Return on Capital Employed rose 89.0% year-over-year to 21.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.43% (up 89.0% YoY) and the FY2025 annual result came in at 21.14%, up 4.0% from the prior year.
- Return on Capital Employed rose to 21.43% in Q1 2026 per UTHR's latest filing, from 21.16% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 51.39% in Q3 2024 and troughed at 16.63% in Q1 2023.
- A 5-year average of 22.81% and a median of 19.84% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 3338 bps in 2024, then plunged 3031 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 17.59% in 2022, then gained by 7 bps to 18.84% in 2023, then surged by 148 bps to 46.75% in 2024, then tumbled by 55 bps to 21.16% in 2025, then grew by 1 bps to 21.43% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 21.43%, 21.16%, and 21.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 3.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.04% |
| Mar 31, 2026 | 21.43% |
| Dec 31, 2025 | 21.16% |
| Sep 30, 2025 | 21.08% |
| Jun 30, 2025 | 19.84% |
| Mar 31, 2025 | 20.54% |
| Dec 31, 2024 | 46.75% |
| Sep 30, 2024 | 51.39% |
| Jun 30, 2024 | 21.87% |
| Mar 31, 2024 | 21.05% |
| Dec 31, 2023 | 18.84% |
| Sep 30, 2023 | 18.01% |
| Jun 30, 2023 | 17.71% |
| Mar 31, 2023 | 16.63% |
| Dec 31, 2022 | 17.59% |
| Sep 30, 2022 | 18.22% |
| Jun 30, 2022 | 17.35% |
| Mar 31, 2022 | 18.28% |
| Dec 31, 2021 | 11.57% |
| Sep 30, 2021 | 9.76% |